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Gregory L. Moneta, MD, Abstracts Section EditorSimultaneous carotid endarterectomy and coronary artery bypass sur-
gery in Canada
Hill MD, Shrive FM, Kennedy J, et al. Neurology 2005;64:1435-7.
Conclusion: In patients undergoing a combination of carotid endar-
terectomy (CEA) and coronary artery bypass grafting (CABG), the adjusted
rate of stroke and death is nearly three times higher than in patients
undergoing CABG alone.
Summary: The performance of simultaneous CEA and CABG is
controversial. A review of 10,561 CEA procedures in Medicare patients
revealed that 2.1% were combined CEA-CABG procedures. In this cohort,
the combined stroke and death rate was 17.7% (J Vasc Surg 2003;37:32-9).
Others have also concluded that the combination of CEA-CABG is an
uncertain indication for CEA (BMC Health Service Research, 2004;4:17).
In this study, the authors examined data obtained from the Canadian
Institutes for Health Information to assess relative risk of stroke and death in
patients undergoing the combination of CEA-CABG vs CABG alone. Data
were obtained from fiscal years 1992/1993 to 2000/2001. Cases were
identified using the Canadian Classification of Procedure Codes (CCP). The
data did not include information on the dates of each procedure within a
given hospital administration. Therefore, all procedures, whether done
combined or sequentially, that occurred on the same hospitalization were
considered combination CEA-CABG procedures. Outcome end points
were in-hospital mortality and postoperative stroke.
In the 9-year period of the study, 131,762 patients underwent CABG,
with 669 patients (0.51%) undergoing a combination of CEA-CABG.
Utilization of the combined CEA-CABG procedure varied according to the
Canadian province examined and increased twofold over the 9-year period
of the study. The increase in utilization was most marked in Manitoba
(sevenfold increase), Alberta (threefold increase), and British Columbia
(threefold increase).
In-hospital mortality was 4.9% (95% confidence interval [CI], 3.3 to
6.6) and the postoperative stroke rate was 8.5% (95% CI, 6.4 to 10.6) in
patients who underwent the combination of CEA-CABG. In patients who
underwent CABG alone, in-hospital mortality was 3.3% (95% CI, 3.2 to
3.4), and the postoperative stroke rate was 1.8% (95% CI, 1.7 to 1.8). With
adjustments, risk of death was not different between the two groups, but
there was an excess risk of stroke in the combined CEA-CABG group of
6.8% (95% CI, 5.9 to 7.7) compared with 1.8% (95% CI, 1.7 to 1.8).
Adjusted combined stroke and death rate for CABG alone was 4.9% (95%
CI, 4.8 to 5.0) compared with 13.0% (95% CI, 10.4 to 16.6) for the
combination of CEA and CABG.
Comment: The data point out the combination of CEA and CABG
carries a high perioperative risk of stroke and death. Despite this, combined
CEA-CABG procedures are offered to an increasing proportion of Canadian
CABG patients. We do not know in this study what proportion of patients
had symptomatic or asymptomatic carotid stenosis or the degree of narrow-
ing of the stenosed arteries. Clearly, there is little evidence to support or
refute the use of combined CEA-CABG procedures. This is an area where
clearly randomized trials would be possible to more fully evaluate the
periprocedural risk of the combination of CEA and CABG.
Results of endovascular repair of inflammatory abdominal aortic aneu-
rysms. A report from the EUROSTAR database
Lange C, Hobo R, Leurs LJ; EUROSTAR Collaborators. Eur J Vasc
Endovasc Surg 2005;29:363-70.
Conclusion: Operative and mid-term results of endovascular repair of
inflammatory abdominal aortic aneurysms (IAAAs) are similar to those after
endovascular repair of standard AAAs. There is residual perianeurysmal
inflammation in many patients.
Summary: There have been conflicting reports regarding the efficacy
of endovascular repair of IAAAs. The authors analyzed the EUROSTAR
registry for patients undergoing endovascular repair of IAAAs and compared
early and mid-term results with those patients undergoing endovascular
repair of standard AAAs. There were 52 patients in the EUROSTAR registry
(1.4%) with an IAAA and 3,611 patients in the registry who underwent
endovascular repair of a standard AAA.Median follow-up in patients with an
IAAAwas 23months (range, 1 to 60months). Eleven of the patients with an
IAAA were analyzed in detail for the effect of endovascular repair on
perianeurysmal fibrosis and ureter entrapment.
Of the patients with an IAAA, 12 (23%) had preoperative renal impair-
ment, and five had hydronephrosis. The presence of an IAAA was associated
with younger age (P  .001; mean difference, 5.9 years; 95% confidence
interval [CI], 3.7 to 7.9 years) and lower pulmonary risk scores (odds ratio,
0.38; 95% CI, 0.19 to 0.74). More device-related stenoses were noted at the
completion of the endovascular repair in the patients with an IAAA than in
1036those with endovascular repair of a standard AAA (odds ratio, 18.1; 95% CI,
3.52 to 93.0). There were no differences in mortality, rupture, or open
conversion in the IAAA vs standard vs AAA groups. In most patients,
aneurysm size regressed irrespective of the initial nature of the aneurysm.
There were no differences between the two groups in hospital stay, preva-
lence of endoleak, or late conversion to open repair.
In the 11 patients with IAAA analyzed in detail, aneurysm wall thick-
ness decreased from 21 mm preoperatively to 17 mm in the early postoper-
ative state and 13 mm in the late postoperative state. Ureteric entrapment
had been observed in 45% of the patients preoperatively and decreased to
27% of the patients after the procedure.
Comment: The data indicate that IAAAs can be repaired with endo-
vascular techniques, with overall similar results to that of standard AAAs.
The effect of endovascular aneurysm repair on resolution of retroperitoneal
fibrosis and ureter entrapment appears similar to that with open repair of
IAAAs. This study is limited by its retrospective nature and by the fact that
the EUROSTAR registry was not designed for analysis of the pathology
associated with IAAAs. Nevertheless, the data, such as they are, suggest
reasonable results with endovascular repair of IAAAs.
Outcome of medical and surgical treatment in patients with acute type
B aortic dissection
Hsu RB, Ho YL, Chen RJ, et al. Ann Thorac Surg 2005;79:790-5.
Conclusion: Eighty-five percent of patients with acute type B aortic
dissection can be treated medically, with near 100% survival at 1 year of these
medically treated patients.
Summary: The authors evaluated 107 patients with acute type B aortic
dissection, all of whom were initially treated medically. Patients with intrac-
table pain, uncontrolled hypertension, severe aortic branch malperfusion, or
expansion of the dissection were treated with surgery. Pleural effusion was
present in 27%, and 8% had leg ischemia. Two patients had aneurysm
enlargement 6.0 cm on serial imaging studies. Overall, 15% of patients
underwent surgical intervention. Eight patients had extra-anatomic bypass
for complication of aortic branch perfusion. Three of these patients died of
central aortic complication (two ruptures, one progression to type A dissec-
tion). Mean follow-up for all patients was 36.1 months (range, 2 to 96
months). Survival rates at 6 months, 1 year, and 5 years of all patients were
96.2%  1.9%, 95.2%  2.1%, and 95.2%  2.1%, respectively.
Comment: Viewed from an intent-to-treat basis, medical treatment of
thoracic dissection is highly successful in 85% of patients. With development
of thoracic stent grafts and their increasing availability, there will surely be a
push for a proactive approach for acutely treating patients with type B
dissection. The results of proactive treatment of type B dissection with
thoracic stent graft in all cases will have to be extraordinary to match the
standards set by this paper. At this point, given the poor outcomes of
extra-anatomic bypass in the patients requiring surgical intervention, it
would appear the most reasonable approach for patients with type B dissec-
tion is initial medical management followed by some sort of central aortic
procedure, whether it be fenestration or stent-graft placement for patients
who fail medical management.
Oral anticoagulation strategies after a first idiopathic venous thrombo-
embolic event
Aujesky D, Smith KJ, Roberts MS. Am J Med 2005; 118:625-35.
Conclusion: Longer periods of anticoagulation with conventional-
intensity warfarin are cost-effective in younger patients. Three months of
anticoagulation is preferred in older patients.
Summary: The authors use a Markov model and decision analysis to
evaluate economic and clinical outcomes of different anticoagulation strat-
egies with warfarin. Six treatment strategies were assessed to treat 40- to
80-year-old men and women after a first idiopathic venous thromboembolic
(VTE) event. Strategies included 3 months, 6 months, 12 months, 24
months, and unlimited duration conventional-intensity anticoagulation
with an international normalized ratio (INR) of 2.0 to 3.0, and finally, a
strategy of unlimited duration low-intensity anticoagulation with an INR
goal of 1.5 to 2.0. The model included age- and sex-specific clinical
parameters and costs. The authors utilized a “societal perspective” to com-
pare strategies in terms of quality adjusted life years, lifetime costs, and
incremental cost-effectiveness ratios.
Incremental cost-effective ratios were lower in younger patients and in
men. This reflected higher bleeding risks of older-age patients and lower risk
of recurrence of VTE among women. Based on a willingness to pay
$50,000 for a quality adjusted life year, a 24-month strategy of conven-
tional intensity warfarin therapy was most cost-effective in 40-year-old men.
The 6-month strategy was preferred in 40-year-old women and 60-year-old
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effective and less costly than other strategies. The risk associated with recurrent
VTE, the disutility of taking warfarin, and major bleeding risk of conventional-
intensity anticoagulation all influenced cost-effectiveness results.
Comment: Treatment of VTE is becoming more individualized. The
strategies outlined in the paper make sense in that they incorporate recent
findings concerning the natural history and the treatment of idiopathic VTE.
By taking into account sex, age, risk of bleeding, and the cost and difficulties
of warfarin therapy, the authors have proposed a reasonable outline for
treatment of idiopathic VTE in both men and women.
Endovascular repair or surveillance of patients with small AAA
Zarins CK, Crabtree T, Arko FR, et al. Eur J Vasc Endovasc Surg 2005;29:
496-503.
Conclusion: In patients with small (4.5 to 5.5 cm) abdominal aortic
aneurysms (AAA), endovascular repair when compared with ultrasound
surveillance and selective open surgery may result in a decreased risk of fatal
aneurysm rupture and aneurysm-related death, with improved patient sur-
vival.
Summary: This was a statistical analysis comparing patients random-
ized to the surveillance arm of the UK Small Aneurysm trial with patients in
a prospective trial of endovascular AAA repair. Endovascular repair patients
were selected from the AneuRx clinical trial cohort that was treated with a
stent-graft from 1997 to 1999 (EVAR Small), with follow-up through
2003. A subgroup of these patients (EVAR Match) who met age and
aneurysm size requirements for inclusion in the UK Small Aneurysm trial
were then compared with the results of the surveillance group (UK Surveil)
with respect to aneurysm rupture, fatal aneurysm rupture, operative mortal-
ity, aneurysm death, and overall mortality. To account for differing lengths
of follow-up end points between the EVARMatch and UK Surveil, patients
were compared using rates per 100 patient years of follow-up.
There were 312 patients in the EVARMatch group. One hundred and
fifty-one patients in the EVAR Small group were excluded for inclusion in
the EVARMatch group because of age60 or76 years or AAA diameter
4 cm. With the exception of age, there were no differences between the
EVAR Small and EVAR Match groups. In comparison with the UK Surveil
group of 527 patients, patients in the EVARMatch group were older (70
4 years vs 69 4 years, P .009) and had larger aneurysms (5.0 0.3 cm.
vs 4.6  0.4 cm, P  .001). There were also fewer women in the EVAR
Match group (7% vs 18%, P  .001). The EVAR Match group also had a
higher prevalence of diabetes mellitus and hypertension and a lower inci-
dence of cigarette smoking than the UK Surveil group.
After adjusting for follow-up time, fatal aneurysm rupture was four
times higher in the UK Surveil group (0.8/100 patient years) than in the
EVAR Match group (0.2/100 patient years). Selected operative morbidity
in the EVARMatch groupwas 1.9%, whereas theUK Surveil groupwas 5.9%
(P .01). Overall ruptures occurred in 1.6% of EVARMatch patients and in
5.1% of UK Surveil patients. This difference was not statistically significant.
Elective operative mortality was significantly higher in the UK Surveil vs
EVAR Match group (5.9% vs 1.9%, P  .01). All-cause mortality was signifi-
cantly higher in theUKSurveil group than in theEVARMatchgroup (8.3/100
patient years vs 6.4/100 patient years, P  .02). Aneurysm-related death was
two times higher in the UK Surveil group (1.6/100 patient years) than in the
EVARMatch group (0.8 vs 100 patient years, P .03).
Comment: This article was accompanied by invited commentaries in
the European Journal of Vascular and Endovascular Surgery. Commentaries
indicate two polarized views of the “interesting” manipulation of statistics
presented in the paper. Dr Brunkwall argued that the “article strongly
supports the need for trials of EVAR vs Surveillance in small aneurysms.” Dr
Powell stated “there is just a suspicion that Zarins and colleagues are using
inappropriate comparisons in an attempt to find new markets for endovas-
cular devices.” As in most cases of widely disparate opinions, there is
probably some truth to both points of view.
Embolic protection devices for carotid artery stenting: Is there a
difference between filter and distal occlusive devices?
Zahn R, Ischinger T, Mark B, et al. J Am Coll Cardiol 2005;45:1769-74.
Conclusion: Filter type embolic protection devices are the currently
preferred method of embolic protection in clinical practice of carotid artery
stenting.
Summary: The authors sought to evaluate filter embolic protection
devices (F-EPD) and distal occlusive protection devices (DO-EPD) in
carotid artery stenting (CAS). Data from July 1996 to July 2003 were
analyzed from the carotid artery stent registry, an ongoing registry of carotid
artery stenting established in 1996 (Eur Heart J 2004;25:1558-8). During
this period, 1,734 patients were entered into the CAS registry. Of these, 176
(24.1%) were treated with DO-EPDs, and 729 patients were treated with an
F-EPD protection device (N  553, 75.9%). Carotid lesions treated in
patients with DO-EPDs had a higher proportion of ulcers, severe calcifica-
tion, longer lesion lengths, and a higher preintervention grade of stenosis (P
 .001). Treatment durations were a mean of 30 minutes in the DO-EPDs
and a mean of 48 minutes in the F-EPDs (P  .001). There was no
difference in clinical events between the two groups of protection devicesexamined. There was no difference in the combined end point of in-hospital
death or stroke between filter andDO-EPDs (adjusted odds ratio, 1.04; 95%
CI, 0.24 to 4.44; P  0.958).
Comment: The data indicate that filter embolic protection devices are
preferred over occlusive embolic protection devices indicated by the larger
percentage of patients were treated with filter embolic protection devices in
this registry. Nevertheless, filter and occlusive protection embolic protection
device appear to have about the same efficacy during CAS. Obviously, likely
what matters is keeping particulate matter out of the brain during CAS. At
this point, it appears embolic protection devices can be chosen based on
relative ease of use and individual operator preference.
MMP-12 has a role in abdominal aortic aneurysms in mice
Longo GM, Buda SJ, Fiotta N, et al. Surgery 2005;137:457-62.
Conclusion: Matrix metalloproteinase-12 (MMP-12) deficiency at-
tenuates aneurysm growth.
Summary: Degradation of elastin and collagen is important in the initia-
tion and expansion of abdominal aortic aneurysms (AAAs). This degradation of
aortic structural proteins is a result, at least in part, of activity by a family of
endopeptidases termed matrix metalloproteinases (MMPs). The authors uti-
lized a murine aneurysm model in this study. Aortic diameters were measured
and compared before and after 10 weeks of induction of AAAs in the model.
Aneurysm induction was achieved by periaortic application of calcium chloride
for 15 minutes. Aortic diameters were then determined for wild-type mice and
MMP-12 knockoutmice. Production ofMMP-12,MMP-2, andMMP-9were
analyzed by zymographic techniques. Macrophage infiltration into the aorta
was also determined with immunohistochemical techniques.
Wild-type mice, after calcium chloride application to the aorta, had
an increase in the aortic diameter of 63%  5%, whereas MMP-12
knockout mice had an increase in aortic diameter of only 26% 14% after
calcium chloride induction. Aortic sections from wild-type mice showed
fragmentation and disruption of medial elastic fibers, whereas aortic
sections from MMP-12 knockout mice showed only focal areas of elastic
lamellae breakdown. There was a significant increase in MMP-12 levels in
wild-type mice after calcium chloride exposure. There was no increase in
MMP-12 levels in MMP-12 knockout mice after calcium chloride expo-
sure. MMP-9 and MMP-2 levels did not change in the wild type and
MMP-12 knockout mice. There were fewer infiltrating macrophages in
the aorta of the MMP-12 knockout mice than in wild-type controls.
Comment: This study supports the hypothesis that MNP-12 plays
some role in AAA pathogenesis. The major source of MMP-12 in vivo is the
macrophage. The macrophage may thus play an important role in aneurysm
formation. Macrophages can convert pro-MMP-12 to an active form and
trigger lysis of the elastic component of the aortic wall, resulting in medial
destruction and aneurysm formation.
Effect of C-reactive protein on gene expression in vascular endothe-
lial cells
Wang Q, Zhu X, Xu Q, et al. Am J Physiol Heart Circ Physiol 2005;288:
H1539-45.
Conclusion:C-reactive protein (CRP), in a dose-dependent fashion, is
associated with specific up- and downregulation of genes that may be
involved in vascular endothelial cell function.
Summary: It is known increased levels of CRP are associated with risk
for coronary artery disease and may have associated risk for arterial disease
elsewhere as well. The authors studied the effects of CRP on gene expression
of vascular endothelial cells. They used microarray analysis along with
polymerase chain reactions to measure gene expression from human vascular
endothelial cells (human aortic endothelial cells and human umbilical vein
endothelial cells). The cells were incubated with CRP at concentrations
varying from 0 to 10 g/mL.
Genetic microarray analysis demonstrated 11 genes had increased
expression, and six genes had decreased expression as defined by a greater
than twofold change in their messenger RNA levels. Interleukin (IL)-8 was
the most significantly upregulated gene (13.6 times baseline) and had a clear
time- and dose-dependent pattern established by quantitative real-time
polymerase chain reaction. CRP enhanced monocyte adhesion to the endo-
thelial cell monolayer by two times (P  .01). This effect was partially
blocked by anti-IL-8 antibody (34.2% inhibition, P  .01). CRP-induced
IL-8 upregulation could be blocked using U0126, an inhibiter of the
extracellular signal-regulated kinase (ERK)mitogen-activated protein kinase
(MAPK) pathway.
Comment:We are all aware of CRP as a marker of cardiovascular risk.
It is, however, unclear whether CRP itself induces changes detrimental to
the vascular system or is merely a byproduct of other biochemical abnormal-
ities that eventually result in increased atherosclerotic risk. These data
suggest that there are genes that are responsive to CRP levels. Many of the
genes in this study shown to be responsive to CRP have broad functional
roles in cell differentiation, cell growth, and vascular remodeling. These data
do not rule out CRP as primarily a byproduct of some other process. They
do, however, indicate CRP itself possesses biologic activity, through modi-
fication of gene expression, that may affect vascular wall biology and, by
inference, atherosclerosis.
